Inmune Bio, Inc. 8-K Filing

Ticker: INMB · Form: 8-K · Filed: Feb 10, 2025 · CIK: 1711754

Inmune Bio, Inc. 8-K Filing Summary
FieldDetail
CompanyInmune Bio, Inc. (INMB)
Form Type8-K
Filed DateFeb 10, 2025
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Inmune Bio, Inc. (ticker: INMB) to the SEC on Feb 10, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma).

How long is this filing?

Inmune Bio, Inc.'s 8-K filing is 2 pages with approximately 607 words. Estimated reading time is 2 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 607 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-02-10 08:30:53

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. INmune Bio Inc. (the "Company") has prepared a slide deck that the Company intends to use in presentations from time to time (the "Investor Presentation") and a slide deck that the Company intends to use in webinar presentations from time to time (the "Webinar Presentation"). Copies of the Investor Presentation and Webinar Presentation are available at the "Investors - Corporate Presentation" section of the Company's website at https://inmunebio.com/index.php/investors/corporate-presentation. The Investor Presentation and Webinar Presentation are furnished as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 and Exhibit 99.2 of this Current Report on Form 8-K is furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 and Exhibit 99.2 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in any such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No . Description 99.1 Investor Presentation 99.2 Webinar Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: February 10, 2025 By: /s/ David Moss Name: David Moss Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.